Skip to main content
Clinical Trials/ITMCTR2000003592
ITMCTR2000003592
Not yet recruiting
Phase 1

The different intervention strategies to explore the objective evaluation of ''blood pathways blocked'' and ''qi pathways blocked'' of coronary atherosclerosis

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Coronary atherosclerotic heart disease
Sponsor
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. The patient meets the diagnostic criteria for coronary atherosclerotic heart disease, has a clear history of myocardial infarction, or coronary angiography or coronary CT confirmed coronary artery stenosis \>\=50%, and the severity of angina pectoris is I\-II/I\-III;
  • 2\. Those who meet the syndrome differentiation criteria of impassable qi and blood vessels in traditional Chinese medicine for coronary heart disease;
  • 3\. Aged 18 to 75 years old;
  • 4\. those who voluntarily sign written informed consent.

Exclusion Criteria

  • (1\) Acute myocardial infarction combined with severe complications such as cardiogenic shock (cannot be corrected by conventional treatment), combined with mechanical complications;
  • (2\) combined with other heart diseases or severe cardiac insufficiency (NYHA cardiac function classification\> III);
  • (3\) Acute coronary syndrome (ACS) patients with asymptomatic or stable symptoms;
  • (4\) Patients with chronic kidney disease with severe heart, lung, liver and other vital organ dysfunction; severe primary diseases, such as hematopoiesis Systemic and/or severe heart, lung, liver and other vital organ dysfunction;
  • (5\) recent cerebrovascular accidents, major operations and trauma history;
  • (6\) Patients with chronic kidney disease and severe heart, lung, liver and other vital organ dysfunction;
  • (7\) Patients with severe uncontrolled hypertension (systolic blood pressure \>\=180mmHg or diastolic blood pressure \>\=110mmHg);
  • (8\) Severe arrhythmia (ventricular bisection, ventricular tachycardia, ventricular fibrillation, third degree atrioventricular block, cardiac Cardiac arrest, severe sinus tachycardia and bradycardia, sick sinus syndrome, reentrant supraventricular tachycardia, arrhythmia leading to hemodynamic changes);
  • (9\) allergic constitution, or more People who are allergic to foods of various drugs, or those who are known to be allergic to the components of the drug;
  • (10\) Patients who have participated in other clinical trials or are taking other proprietary Chinese medicines within one month;

Outcomes

Primary Outcomes

Not specified

Similar Trials